| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 33 | 2016 | 454 | 1.390 |
Why?
|
| Myelodysplastic Syndromes | 11 | 2014 | 68 | 1.250 |
Why?
|
| Racemases and Epimerases | 15 | 2006 | 24 | 1.220 |
Why?
|
| Adenocarcinoma | 20 | 2014 | 322 | 1.120 |
Why?
|
| Prostatic Neoplasms | 15 | 2006 | 326 | 0.940 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 39 | 0.920 |
Why?
|
| RNA-Binding Proteins | 13 | 2014 | 384 | 0.860 |
Why?
|
| Immunohistochemistry | 28 | 2016 | 846 | 0.840 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2016 | 65 | 0.740 |
Why?
|
| Herpesvirus 4, Human | 11 | 2016 | 181 | 0.700 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 320 | 0.660 |
Why?
|
| Bone Marrow | 15 | 2014 | 174 | 0.570 |
Why?
|
| Neoplasm Proteins | 9 | 2012 | 276 | 0.560 |
Why?
|
| Biopsy, Needle | 8 | 2006 | 126 | 0.550 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2016 | 155 | 0.520 |
Why?
|
| Hodgkin Disease | 3 | 2013 | 56 | 0.480 |
Why?
|
| Mutation | 13 | 2024 | 2427 | 0.480 |
Why?
|
| Humans | 143 | 2024 | 59332 | 0.480 |
Why?
|
| Graft vs Host Disease | 3 | 2013 | 99 | 0.440 |
Why?
|
| Lymphoma, Follicular | 2 | 2013 | 15 | 0.440 |
Why?
|
| Male | 94 | 2024 | 27515 | 0.430 |
Why?
|
| Clonal Evolution | 1 | 2013 | 3 | 0.430 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 133 | 0.420 |
Why?
|
| Diabetes Mellitus, Experimental | 8 | 2000 | 195 | 0.420 |
Why?
|
| Aged, 80 and over | 29 | 2024 | 5067 | 0.410 |
Why?
|
| Killer Cells, Natural | 12 | 2010 | 214 | 0.400 |
Why?
|
| Middle Aged | 50 | 2024 | 16241 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 5 | 2016 | 59 | 0.390 |
Why?
|
| Female | 82 | 2024 | 30832 | 0.390 |
Why?
|
| Bone Marrow Diseases | 2 | 2008 | 14 | 0.390 |
Why?
|
| Lymphoproliferative Disorders | 6 | 2012 | 35 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 21 | 2006 | 870 | 0.380 |
Why?
|
| Carcinoma | 5 | 2006 | 117 | 0.370 |
Why?
|
| T-Lymphocytes | 17 | 2012 | 963 | 0.370 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 1999 | 51 | 0.360 |
Why?
|
| Islets of Langerhans | 7 | 2007 | 267 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2018 | 163 | 0.360 |
Why?
|
| Aged | 45 | 2024 | 13298 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2018 | 75 | 0.350 |
Why?
|
| Precancerous Conditions | 4 | 2014 | 72 | 0.350 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 114 | 0.340 |
Why?
|
| Colonic Neoplasms | 6 | 2003 | 213 | 0.330 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2010 | 48 | 0.320 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2008 | 4 | 0.320 |
Why?
|
| Prognosis | 15 | 2016 | 1564 | 0.320 |
Why?
|
| Lymphocytes | 11 | 2008 | 194 | 0.310 |
Why?
|
| Eukaryotic Initiation Factor-2 | 4 | 2008 | 14 | 0.310 |
Why?
|
| Rats | 31 | 2009 | 1907 | 0.300 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2008 | 13 | 0.300 |
Why?
|
| Histocompatibility Antigens | 10 | 1994 | 107 | 0.300 |
Why?
|
| Adult | 40 | 2024 | 15738 | 0.300 |
Why?
|
| Rats, Inbred Strains | 9 | 2009 | 151 | 0.300 |
Why?
|
| B-Lymphocytes | 7 | 2016 | 548 | 0.290 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2011 | 145 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 250 | 0.280 |
Why?
|
| Myeloproliferative Disorders | 4 | 2014 | 16 | 0.280 |
Why?
|
| DNA-Binding Proteins | 4 | 2024 | 1128 | 0.280 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2009 | 607 | 0.270 |
Why?
|
| Prostate | 6 | 2006 | 54 | 0.270 |
Why?
|
| Neoplasm Staging | 9 | 2016 | 450 | 0.260 |
Why?
|
| Lymphoma | 7 | 2012 | 98 | 0.260 |
Why?
|
| Melanoma | 4 | 2014 | 334 | 0.250 |
Why?
|
| Immunoenzyme Techniques | 16 | 2011 | 104 | 0.250 |
Why?
|
| Dioxygenases | 2 | 2024 | 25 | 0.250 |
Why?
|
| Receptors, Antigen, B-Cell | 7 | 1988 | 58 | 0.250 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2016 | 60 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2016 | 484 | 0.240 |
Why?
|
| Membrane Proteins | 7 | 2010 | 843 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 40 | 0.240 |
Why?
|
| Cytoskeletal Proteins | 3 | 2010 | 194 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 99 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2016 | 299 | 0.230 |
Why?
|
| Immunoglobulin lambda-Chains | 3 | 2022 | 10 | 0.230 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2014 | 48 | 0.220 |
Why?
|
| Sensitivity and Specificity | 12 | 2016 | 1093 | 0.220 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2013 | 90 | 0.220 |
Why?
|
| Macrophages | 6 | 2011 | 1006 | 0.220 |
Why?
|
| Phenotype | 13 | 2016 | 1157 | 0.220 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2022 | 9 | 0.220 |
Why?
|
| Cytoskeleton | 6 | 1988 | 140 | 0.220 |
Why?
|
| Nevus | 2 | 2014 | 18 | 0.220 |
Why?
|
| Cytosine | 2 | 2014 | 30 | 0.210 |
Why?
|
| Membrane Glycoproteins | 6 | 2011 | 669 | 0.210 |
Why?
|
| Bone Marrow Cells | 8 | 2009 | 231 | 0.210 |
Why?
|
| Peptide Initiation Factors | 2 | 2001 | 32 | 0.210 |
Why?
|
| Rats, Inbred BB | 5 | 1994 | 134 | 0.210 |
Why?
|
| Radiation Tolerance | 4 | 2016 | 47 | 0.200 |
Why?
|
| Lung Neoplasms | 5 | 2014 | 547 | 0.200 |
Why?
|
| Animals | 54 | 2016 | 19616 | 0.200 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2013 | 9 | 0.200 |
Why?
|
| Epigenesis, Genetic | 3 | 2016 | 351 | 0.200 |
Why?
|
| Immunologic Capping | 7 | 1983 | 10 | 0.200 |
Why?
|
| Intestinal Mucosa | 5 | 2010 | 221 | 0.200 |
Why?
|
| Neoplasms | 7 | 2016 | 1234 | 0.190 |
Why?
|
| Flow Cytometry | 7 | 2009 | 671 | 0.190 |
Why?
|
| 5-Methylcytosine | 3 | 2016 | 20 | 0.190 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2011 | 28 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2024 | 315 | 0.190 |
Why?
|
| Survival Analysis | 9 | 2018 | 553 | 0.180 |
Why?
|
| Spleen | 16 | 2012 | 485 | 0.180 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2008 | 236 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 3 | 2010 | 316 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2014 | 399 | 0.180 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.180 |
Why?
|
| Leukocytosis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Chromosome Aberrations | 4 | 2008 | 64 | 0.170 |
Why?
|
| Diagnosis, Differential | 9 | 2018 | 898 | 0.170 |
Why?
|
| Colon | 3 | 2003 | 137 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 6 | 2016 | 500 | 0.170 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2011 | 12 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2011 | 17 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2000 | 165 | 0.170 |
Why?
|
| Oncogenes | 2 | 2018 | 68 | 0.170 |
Why?
|
| Adenoma | 5 | 2009 | 63 | 0.160 |
Why?
|
| Eosinophilia | 3 | 2008 | 28 | 0.160 |
Why?
|
| Endometrial Neoplasms | 2 | 2011 | 55 | 0.160 |
Why?
|
| Islets of Langerhans Transplantation | 4 | 2007 | 170 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2018 | 17 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 33 | 0.160 |
Why?
|
| Carcinoma in Situ | 2 | 2010 | 32 | 0.150 |
Why?
|
| Rats, Inbred Lew | 10 | 2009 | 109 | 0.150 |
Why?
|
| Carcinoma, Papillary | 2 | 2008 | 36 | 0.150 |
Why?
|
| Urothelium | 2 | 2016 | 22 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 6 | 0.150 |
Why?
|
| Receptor, ErbB-4 | 1 | 2018 | 8 | 0.150 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2018 | 10 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2010 | 104 | 0.150 |
Why?
|
| Heterozygote | 2 | 2016 | 168 | 0.150 |
Why?
|
| Leukemia | 4 | 2013 | 53 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 677 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 2 | 2008 | 76 | 0.150 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2008 | 7 | 0.150 |
Why?
|
| Intestinal Neoplasms | 1 | 1997 | 13 | 0.150 |
Why?
|
| Skin Neoplasms | 3 | 2014 | 404 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2016 | 1025 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2016 | 5 | 0.140 |
Why?
|
| Papillomavirus Infections | 2 | 2011 | 124 | 0.140 |
Why?
|
| Herpesviridae Infections | 3 | 1996 | 28 | 0.140 |
Why?
|
| Rats, Mutant Strains | 4 | 1991 | 10 | 0.140 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 4 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 298 | 0.130 |
Why?
|
| Hemoglobin C | 1 | 2016 | 2 | 0.130 |
Why?
|
| Anemia, Hypochromic | 1 | 2016 | 5 | 0.130 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2016 | 4 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2007 | 113 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 53 | 0.130 |
Why?
|
| Sarcoma | 1 | 2016 | 34 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 209 | 0.130 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 2 | 1993 | 3 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 22 | 0.130 |
Why?
|
| Burkitt Lymphoma | 2 | 2016 | 56 | 0.130 |
Why?
|
| Eukaryotic Initiation Factor-4E | 3 | 2008 | 16 | 0.130 |
Why?
|
| Cell Polarity | 3 | 2010 | 110 | 0.130 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2006 | 4 | 0.130 |
Why?
|
| Treatment Failure | 2 | 2013 | 187 | 0.130 |
Why?
|
| Adenoma, Villous | 1 | 1995 | 1 | 0.120 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 3 | 2003 | 14 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2003 | 15 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2003 | 52 | 0.120 |
Why?
|
| Immunophenotyping | 6 | 2016 | 191 | 0.120 |
Why?
|
| DNA Damage | 3 | 2016 | 277 | 0.120 |
Why?
|
| Pneumonia | 2 | 2013 | 263 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2009 | 192 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 4 | 0.120 |
Why?
|
| Fixatives | 1 | 2014 | 17 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 3 | 2012 | 201 | 0.120 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 91 | 0.120 |
Why?
|
| Salvage Therapy | 2 | 2013 | 73 | 0.120 |
Why?
|
| ADP Ribose Transferases | 2 | 1991 | 62 | 0.120 |
Why?
|
| Disease Progression | 6 | 2024 | 1040 | 0.120 |
Why?
|
| Lung | 3 | 2008 | 825 | 0.110 |
Why?
|
| Cytotoxins | 1 | 1994 | 12 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 26 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 60 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 25 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 21 | 0.110 |
Why?
|
| Dendritic Cells | 2 | 2013 | 509 | 0.110 |
Why?
|
| Antigens, CD34 | 2 | 2011 | 53 | 0.110 |
Why?
|
| Antigens, Surface | 7 | 2002 | 191 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2014 | 33 | 0.110 |
Why?
|
| Graft Rejection | 4 | 2007 | 257 | 0.110 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2007 | 238 | 0.110 |
Why?
|
| Histiocytosis, Sinus | 1 | 1993 | 2 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2014 | 387 | 0.110 |
Why?
|
| Mice | 21 | 2016 | 10259 | 0.110 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 11 | 0.110 |
Why?
|
| Biopsy | 5 | 2016 | 373 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 74 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 26 | 0.100 |
Why?
|
| Young Adult | 7 | 2018 | 4321 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 50 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2013 | 112 | 0.100 |
Why?
|
| Skin Transplantation | 4 | 2002 | 151 | 0.100 |
Why?
|
| Gastric Mucosa | 2 | 2010 | 48 | 0.100 |
Why?
|
| Lymphocytic Choriomeningitis | 4 | 2002 | 51 | 0.100 |
Why?
|
| Erythrocytes | 2 | 1987 | 155 | 0.100 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 72 | 0.100 |
Why?
|
| CD40 Ligand | 6 | 2002 | 162 | 0.100 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2013 | 68 | 0.100 |
Why?
|
| Autoimmunity | 2 | 2006 | 223 | 0.100 |
Why?
|
| Adrenal Glands | 1 | 2012 | 29 | 0.100 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 12 | 2016 | 3190 | 0.100 |
Why?
|
| Tumor Virus Infections | 3 | 1997 | 38 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 233 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2013 | 265 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 2012 | 51 | 0.090 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2012 | 143 | 0.090 |
Why?
|
| Pleural Neoplasms | 1 | 2011 | 17 | 0.090 |
Why?
|
| Graft Survival | 3 | 2002 | 279 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2011 | 26 | 0.090 |
Why?
|
| Antigens, Neoplasm | 3 | 2008 | 134 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 23 | 0.090 |
Why?
|
| Megakaryocytes | 1 | 2011 | 20 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2012 | 87 | 0.090 |
Why?
|
| Epithelium | 1 | 2011 | 97 | 0.090 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2010 | 4 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 274 | 0.090 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 19 | 0.090 |
Why?
|
| Endopeptidases | 1 | 2011 | 67 | 0.090 |
Why?
|
| Lymphocyte Depletion | 7 | 2002 | 95 | 0.090 |
Why?
|
| Meningeal Neoplasms | 1 | 2011 | 57 | 0.090 |
Why?
|
| Meningioma | 1 | 2011 | 58 | 0.090 |
Why?
|
| Immunization | 2 | 2009 | 127 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2008 | 196 | 0.090 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 64 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 193 | 0.090 |
Why?
|
| Stomach Diseases | 1 | 2010 | 9 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2014 | 595 | 0.090 |
Why?
|
| Hematopoiesis | 3 | 2008 | 123 | 0.090 |
Why?
|
| Palliative Care | 1 | 2013 | 202 | 0.090 |
Why?
|
| Time Factors | 9 | 2014 | 3567 | 0.090 |
Why?
|
| Immune Tolerance | 3 | 2000 | 169 | 0.090 |
Why?
|
| Karyotyping | 6 | 2011 | 45 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2010 | 98 | 0.090 |
Why?
|
| Autoimmune Diseases | 3 | 1991 | 222 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 233 | 0.090 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 375 | 0.080 |
Why?
|
| Lymphopenia | 2 | 1987 | 35 | 0.080 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 2009 | 5 | 0.080 |
Why?
|
| Basophils | 1 | 2009 | 14 | 0.080 |
Why?
|
| Survival Rate | 5 | 2011 | 787 | 0.080 |
Why?
|
| Homeostasis | 1 | 2012 | 340 | 0.080 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 195 | 0.080 |
Why?
|
| Adolescent | 7 | 2018 | 5918 | 0.080 |
Why?
|
| Diabetes Insipidus | 2 | 1987 | 3 | 0.080 |
Why?
|
| CD55 Antigens | 1 | 2008 | 2 | 0.080 |
Why?
|
| CD59 Antigens | 1 | 2008 | 3 | 0.080 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 34 | 0.080 |
Why?
|
| Sepsis | 1 | 2013 | 280 | 0.080 |
Why?
|
| Gene Rearrangement | 4 | 2014 | 38 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 2 | 1999 | 16 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 697 | 0.080 |
Why?
|
| X Chromosome | 1 | 1989 | 44 | 0.080 |
Why?
|
| Glucose | 1 | 2012 | 444 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 2 | 1980 | 49 | 0.080 |
Why?
|
| Lymphatic Diseases | 2 | 1985 | 11 | 0.080 |
Why?
|
| Erythroblasts | 1 | 2008 | 15 | 0.080 |
Why?
|
| Tissue Embedding | 1 | 2008 | 3 | 0.080 |
Why?
|
| Monocytes | 2 | 2008 | 351 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2009 | 110 | 0.080 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2008 | 19 | 0.080 |
Why?
|
| Erythroid Precursor Cells | 1 | 2008 | 20 | 0.080 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 21 | 0.080 |
Why?
|
| Apoptosis | 5 | 2016 | 1038 | 0.080 |
Why?
|
| Lipidoses | 1 | 1988 | 1 | 0.080 |
Why?
|
| Langerhans Cells | 1 | 1988 | 11 | 0.080 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 17 | 0.080 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1988 | 14 | 0.080 |
Why?
|
| Polyploidy | 1 | 2008 | 11 | 0.080 |
Why?
|
| Viral Matrix Proteins | 3 | 1997 | 51 | 0.080 |
Why?
|
| Mosaicism | 1 | 2008 | 25 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 63 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 77 | 0.080 |
Why?
|
| Actinin | 1 | 1988 | 9 | 0.080 |
Why?
|
| Antigens | 4 | 2002 | 146 | 0.080 |
Why?
|
| Mice, SCID | 6 | 2008 | 506 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1988 | 43 | 0.070 |
Why?
|
| Concanavalin A | 3 | 1986 | 40 | 0.070 |
Why?
|
| Immunoproliferative Disorders | 1 | 1987 | 1 | 0.070 |
Why?
|
| Disease Models, Animal | 4 | 2007 | 2062 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 2323 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 54 | 0.070 |
Why?
|
| Neutropenia | 1 | 2008 | 66 | 0.070 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 7 | 0.070 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 5 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 16 | 0.070 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 1 | 2008 | 61 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2011 | 262 | 0.070 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 1987 | 2 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1986 | 196 | 0.070 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2000 | 52 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2008 | 172 | 0.070 |
Why?
|
| Cytokines | 1 | 1991 | 906 | 0.070 |
Why?
|
| Connective Tissue Diseases | 1 | 1987 | 10 | 0.070 |
Why?
|
| Lymph Nodes | 6 | 1999 | 211 | 0.070 |
Why?
|
| Mediastinum | 1 | 1987 | 23 | 0.070 |
Why?
|
| Aging | 4 | 1981 | 723 | 0.070 |
Why?
|
| Phagocytosis | 2 | 1987 | 252 | 0.070 |
Why?
|
| Massachusetts | 5 | 2016 | 2083 | 0.070 |
Why?
|
| Bone and Bones | 1 | 1988 | 155 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 291 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 52 | 0.070 |
Why?
|
| Anemia, Refractory | 1 | 2006 | 1 | 0.070 |
Why?
|
| Thrombocytosis | 1 | 2006 | 3 | 0.070 |
Why?
|
| Receptors, Fc | 3 | 1983 | 21 | 0.070 |
Why?
|
| Neural Tube Defects | 1 | 2006 | 27 | 0.070 |
Why?
|
| Breast | 1 | 2008 | 173 | 0.070 |
Why?
|
| Cell Separation | 2 | 1984 | 149 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2014 | 111 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 1993 | 29 | 0.070 |
Why?
|
| Liver | 4 | 2006 | 785 | 0.070 |
Why?
|
| Repressor Proteins | 2 | 2024 | 336 | 0.070 |
Why?
|
| Blood Transfusion | 3 | 2001 | 148 | 0.070 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 64 | 0.070 |
Why?
|
| Lymphocyte Activation | 7 | 2008 | 740 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 1549 | 0.060 |
Why?
|
| G(M2) Ganglioside | 1 | 2005 | 9 | 0.060 |
Why?
|
| Jejunal Neoplasms | 1 | 1985 | 4 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 242 | 0.060 |
Why?
|
| Mice, Inbred NOD | 5 | 2008 | 515 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 19 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2008 | 222 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2005 | 228 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 2 | 1998 | 21 | 0.060 |
Why?
|
| Primary Myelofibrosis | 1 | 1985 | 10 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2012 | 330 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5142 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2005 | 100 | 0.060 |
Why?
|
| Dendrites | 1 | 1985 | 56 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2005 | 59 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 643 | 0.060 |
Why?
|
| Rats, Inbred BN | 3 | 1981 | 25 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2016 | 5979 | 0.060 |
Why?
|
| Receptors, Antigen | 2 | 1984 | 6 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 28 | 0.060 |
Why?
|
| Thymoma | 1 | 1984 | 11 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 533 | 0.060 |
Why?
|
| Thymus Neoplasms | 1 | 1984 | 21 | 0.060 |
Why?
|
| Endocytosis | 2 | 1982 | 148 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1295 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 86 | 0.060 |
Why?
|
| Cytotoxicity, Immunologic | 4 | 1990 | 142 | 0.060 |
Why?
|
| Gene Expression | 3 | 2007 | 808 | 0.050 |
Why?
|
| Nevus, Pigmented | 1 | 2003 | 20 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 21 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2003 | 29 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 2005 | 1470 | 0.050 |
Why?
|
| Poly I-C | 4 | 2009 | 74 | 0.050 |
Why?
|
| Inflammation | 4 | 1994 | 1101 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2011 | 944 | 0.050 |
Why?
|
| Trifluoperazine | 1 | 1982 | 3 | 0.050 |
Why?
|
| Prostatic Hyperplasia | 1 | 2002 | 5 | 0.050 |
Why?
|
| Infant | 4 | 2016 | 1527 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 131 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2016 | 861 | 0.050 |
Why?
|
| Lymphocytic choriomeningitis virus | 2 | 2000 | 83 | 0.050 |
Why?
|
| Bone Marrow Examination | 3 | 2014 | 8 | 0.050 |
Why?
|
| Transplantation Tolerance | 1 | 2002 | 65 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2014 | 275 | 0.050 |
Why?
|
| Germinoma | 1 | 2001 | 1 | 0.050 |
Why?
|
| Splenic Neoplasms | 1 | 1981 | 7 | 0.050 |
Why?
|
| Eye Neoplasms | 1 | 2001 | 17 | 0.050 |
Why?
|
| Retinoblastoma | 1 | 2001 | 27 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2001 | 9 | 0.050 |
Why?
|
| Fibroblasts | 3 | 2016 | 367 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 32 | 0.050 |
Why?
|
| CD8 Antigens | 3 | 2002 | 53 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 40 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2016 | 1221 | 0.050 |
Why?
|
| Vincristine | 2 | 2014 | 26 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2014 | 71 | 0.050 |
Why?
|
| HLA Antigens | 1 | 1981 | 59 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 6 | 1998 | 219 | 0.050 |
Why?
|
| Prednisone | 2 | 2014 | 80 | 0.050 |
Why?
|
| DNA, Neoplasm | 3 | 2003 | 51 | 0.050 |
Why?
|
| ras Proteins | 2 | 2014 | 78 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2014 | 99 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 6 | 2002 | 880 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2008 | 461 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2012 | 25 | 0.040 |
Why?
|
| Transplantation Chimera | 1 | 2000 | 37 | 0.040 |
Why?
|
| Biomarkers | 3 | 2010 | 1205 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 1456 | 0.040 |
Why?
|
| Molecular Weight | 3 | 2002 | 187 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2001 | 609 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 2437 | 0.040 |
Why?
|
| Syndrome | 3 | 1990 | 173 | 0.040 |
Why?
|
| Cell Count | 2 | 2011 | 129 | 0.040 |
Why?
|
| Microspheres | 3 | 2005 | 53 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 1980 | 63 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 231 | 0.040 |
Why?
|
| Antigens, CD | 3 | 2007 | 343 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 1518 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 1129 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 2 | 2009 | 9 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2001 | 1456 | 0.040 |
Why?
|
| Infectious Mononucleosis | 3 | 1989 | 35 | 0.040 |
Why?
|
| Cervix Uteri | 2 | 2011 | 57 | 0.040 |
Why?
|
| Child | 6 | 2006 | 4300 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 31 | 0.040 |
Why?
|
| Colchicine | 5 | 1987 | 27 | 0.040 |
Why?
|
| Rituximab | 2 | 2012 | 82 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 1996 | 98 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 525 | 0.040 |
Why?
|
| Transplantation Conditioning | 3 | 2008 | 94 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2001 | 179 | 0.040 |
Why?
|
| Keratins | 3 | 2004 | 31 | 0.040 |
Why?
|
| Reference Values | 1 | 1999 | 323 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2012 | 1988 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 137 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
| Immunity, Innate | 5 | 2000 | 766 | 0.040 |
Why?
|
| Hypohidrosis | 1 | 1998 | 3 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 3 | 2009 | 69 | 0.040 |
Why?
|
| Centrosome | 1 | 1998 | 71 | 0.040 |
Why?
|
| Alopecia | 1 | 1998 | 26 | 0.040 |
Why?
|
| Cell Transformation, Viral | 2 | 1996 | 16 | 0.040 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 3 | 0.040 |
Why?
|
| Sweat Gland Neoplasms | 1 | 1998 | 20 | 0.040 |
Why?
|
| Pruritus | 1 | 1998 | 29 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 1998 | 26 | 0.040 |
Why?
|
| Cells, Cultured | 5 | 1995 | 2103 | 0.040 |
Why?
|
| Melanocytes | 2 | 2012 | 78 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1997 | 14 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2010 | 1838 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 73 | 0.040 |
Why?
|
| Immunologic Techniques | 1 | 1977 | 12 | 0.040 |
Why?
|
| Cricetinae | 2 | 2011 | 377 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 2 | 2008 | 36 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 1998 | 454 | 0.040 |
Why?
|
| Radiography, Abdominal | 1 | 1997 | 27 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1995 | 94 | 0.040 |
Why?
|
| Cell Line | 10 | 1993 | 2014 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 580 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2016 | 6 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 1997 | 138 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 354 | 0.030 |
Why?
|
| Janus Kinase 2 | 2 | 2006 | 13 | 0.030 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.030 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Tuberculosis, Miliary | 1 | 1996 | 3 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 742 | 0.030 |
Why?
|
| Antigens, Viral | 2 | 1987 | 131 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1996 | 7 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2011 | 926 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 53 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 193 | 0.030 |
Why?
|
| Bronchi | 1 | 1996 | 77 | 0.030 |
Why?
|
| HeLa Cells | 3 | 2011 | 527 | 0.030 |
Why?
|
| Intestine, Large | 1 | 1995 | 5 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2012 | 645 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 141 | 0.030 |
Why?
|
| DNA | 2 | 2006 | 793 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 201 | 0.030 |
Why?
|
| In Vitro Techniques | 4 | 1990 | 475 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 425 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 258 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 255 | 0.030 |
Why?
|
| CD5 Antigens | 2 | 1993 | 18 | 0.030 |
Why?
|
| Lymphoid Tissue | 3 | 2002 | 55 | 0.030 |
Why?
|
| Cell Fusion | 1 | 1995 | 45 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2009 | 3095 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 23 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.030 |
Why?
|
| Lipids | 2 | 2012 | 305 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 32 | 0.030 |
Why?
|
| Syndecan-1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1994 | 3 | 0.030 |
Why?
|
| Acute Disease | 4 | 1995 | 658 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 43 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2016 | 2890 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1994 | 27 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1995 | 84 | 0.030 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1984 | 34 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 1991 | 106 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 40 | 0.030 |
Why?
|
| Thy-1 Antigens | 2 | 1984 | 21 | 0.030 |
Why?
|
| Polyomavirus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1995 | 113 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1994 | 37 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 41 | 0.030 |
Why?
|
| Solubility | 2 | 1984 | 173 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 133 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 1994 | 46 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 215 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 192 | 0.030 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2013 | 5 | 0.030 |
Why?
|
| Automation | 2 | 2003 | 58 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2003 | 44 | 0.030 |
Why?
|
| Biotechnology | 2 | 2003 | 42 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 1993 | 39 | 0.030 |
Why?
|
| Deoxyribonuclease I | 1 | 1993 | 38 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 28 | 0.030 |
Why?
|
| Collagen | 2 | 2005 | 121 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 32 | 0.030 |
Why?
|
| CpG Islands | 1 | 2014 | 212 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 34 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1976 | 324 | 0.030 |
Why?
|
| Cytochalasins | 3 | 1981 | 4 | 0.030 |
Why?
|
| Eosinophils | 1 | 1993 | 51 | 0.030 |
Why?
|
| Cell Division | 3 | 2003 | 442 | 0.030 |
Why?
|
| Plasma Cells | 1 | 1993 | 48 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2012 | 19 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1993 | 68 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2012 | 40 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 43 | 0.030 |
Why?
|
| Receptors, Concanavalin A | 2 | 1982 | 2 | 0.030 |
Why?
|
| Serine | 1 | 2012 | 83 | 0.020 |
Why?
|
| Cerebellar Neoplasms | 1 | 1992 | 9 | 0.020 |
Why?
|
| Protein Stability | 1 | 2012 | 82 | 0.020 |
Why?
|
| Point Mutation | 3 | 1997 | 162 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2003 | 287 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 20 | 0.020 |
Why?
|
| Fasting | 1 | 2012 | 51 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1984 | 179 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2012 | 73 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 98 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2012 | 75 | 0.020 |
Why?
|
| Membrane Fluidity | 2 | 1982 | 14 | 0.020 |
Why?
|
| Pleura | 1 | 2011 | 11 | 0.020 |
Why?
|
| Autoantibodies | 3 | 1987 | 174 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 353 | 0.020 |
Why?
|
| Mice, Inbred CBA | 2 | 2002 | 82 | 0.020 |
Why?
|
| Peritoneum | 1 | 2011 | 25 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2012 | 222 | 0.020 |
Why?
|
| Endometrium | 1 | 2011 | 28 | 0.020 |
Why?
|
| Adiposity | 1 | 2012 | 81 | 0.020 |
Why?
|
| Virus Physiological Phenomena | 1 | 1991 | 7 | 0.020 |
Why?
|
| Frozen Sections | 2 | 2003 | 10 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 179 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2011 | 85 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2008 | 735 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 104 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 148 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1997 | 1130 | 0.020 |
Why?
|
| California | 1 | 2011 | 160 | 0.020 |
Why?
|
| NADPH Oxidase 2 | 1 | 2011 | 35 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2012 | 68 | 0.020 |
Why?
|
| Qa-SNARE Proteins | 1 | 2010 | 18 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 29 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 1991 | 140 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 659 | 0.020 |
Why?
|
| Gastritis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Contractile Proteins | 2 | 1980 | 14 | 0.020 |
Why?
|
| Cricetulus | 1 | 2011 | 102 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2012 | 204 | 0.020 |
Why?
|
| Goats | 2 | 1981 | 9 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2012 | 194 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1991 | 155 | 0.020 |
Why?
|
| CHO Cells | 1 | 2011 | 191 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 324 | 0.020 |
Why?
|
| Tryptophan | 1 | 1990 | 55 | 0.020 |
Why?
|
| Muscular Diseases | 1 | 1990 | 45 | 0.020 |
Why?
|
| Hemocyanins | 2 | 1980 | 23 | 0.020 |
Why?
|
| Parvoviridae Infections | 1 | 1990 | 23 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 378 | 0.020 |
Why?
|
| Ligands | 2 | 2000 | 422 | 0.020 |
Why?
|
| Enterovirus Infections | 1 | 2009 | 11 | 0.020 |
Why?
|
| Base Sequence | 3 | 2003 | 1312 | 0.020 |
Why?
|
| Enterovirus B, Human | 1 | 2009 | 22 | 0.020 |
Why?
|
| Disease Susceptibility | 2 | 1987 | 158 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 422 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1991 | 309 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Cisplatin | 1 | 1990 | 119 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 301 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2009 | 20 | 0.020 |
Why?
|
| Pancreas | 1 | 2010 | 147 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2009 | 20 | 0.020 |
Why?
|
| Protein Biosynthesis | 2 | 2002 | 293 | 0.020 |
Why?
|
| Vaccinia virus | 1 | 2009 | 71 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 4999 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 672 | 0.020 |
Why?
|
| Esophagus | 1 | 2009 | 51 | 0.020 |
Why?
|
| Mitosis | 2 | 2008 | 208 | 0.020 |
Why?
|
| United States | 2 | 2014 | 7493 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1989 | 101 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 220 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1991 | 449 | 0.020 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 25 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 1990 | 305 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2008 | 18 | 0.020 |
Why?
|
| Cell Cycle | 2 | 1990 | 379 | 0.020 |
Why?
|
| Sclerosis | 1 | 1988 | 7 | 0.020 |
Why?
|
| Leukopenia | 1 | 2008 | 16 | 0.020 |
Why?
|
| Isoelectric Point | 1 | 1988 | 14 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 591 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1988 | 11 | 0.020 |
Why?
|
| Actins | 2 | 2001 | 260 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 55 | 0.020 |
Why?
|
| Paraproteinemias | 1 | 2008 | 18 | 0.020 |
Why?
|
| Granulocytes | 1 | 2008 | 67 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 371 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1986 | 48 | 0.020 |
Why?
|
| Histiocytes | 1 | 1987 | 5 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 96 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 1988 | 120 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1987 | 29 | 0.020 |
Why?
|
| Epitopes | 2 | 2005 | 298 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 687 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2008 | 129 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 190 | 0.020 |
Why?
|
| Pancytopenia | 1 | 1987 | 7 | 0.020 |
Why?
|
| Intermediate Filament Proteins | 1 | 1987 | 19 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 177 | 0.020 |
Why?
|
| Intermediate Filaments | 1 | 1986 | 8 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 261 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1986 | 1 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 1997 | 114 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 1977 | 0.020 |
Why?
|
| Cell Survival | 3 | 1990 | 553 | 0.020 |
Why?
|
| Fibrosis | 1 | 1987 | 151 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 24 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2003 | 1907 | 0.020 |
Why?
|
| Radiography | 1 | 1988 | 505 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 695 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 11 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2005 | 28 | 0.020 |
Why?
|
| Mice, Inbred AKR | 1 | 2005 | 12 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1986 | 164 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1986 | 176 | 0.020 |
Why?
|
| Avian Leukosis Virus | 1 | 1985 | 3 | 0.020 |
Why?
|
| S100 Proteins | 1 | 1985 | 21 | 0.020 |
Why?
|
| Kinetics | 2 | 2002 | 735 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 603 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2005 | 102 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 2005 | 99 | 0.020 |
Why?
|
| Arthritis | 1 | 2005 | 49 | 0.020 |
Why?
|
| Pituitary Gland, Posterior | 1 | 1985 | 19 | 0.020 |
Why?
|
| Hemangiosarcoma | 1 | 1985 | 24 | 0.020 |
Why?
|
| Skin | 3 | 1990 | 351 | 0.020 |
Why?
|
| Pituitary Gland | 2 | 1987 | 49 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1986 | 275 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2008 | 636 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 117 | 0.010 |
Why?
|
| Liposomes | 1 | 1984 | 98 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 919 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 1984 | 98 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1232 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2008 | 1311 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 1990 | 53 | 0.010 |
Why?
|
| Octoxynol | 1 | 1983 | 12 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1984 | 88 | 0.010 |
Why?
|
| Hepatitis, Viral, Animal | 1 | 1983 | 1 | 0.010 |
Why?
|
| DNA Probes | 1 | 2003 | 35 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 34 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1985 | 233 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2003 | 52 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1448 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 172 | 0.010 |
Why?
|
| Diffusion | 1 | 1983 | 84 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 644 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 256 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2002 | 8 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1992 | 2034 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 45 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2002 | 57 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2002 | 41 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2002 | 40 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1983 | 162 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 314 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 2352 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 82 | 0.010 |
Why?
|
| Contrast Media | 1 | 1984 | 408 | 0.010 |
Why?
|
| Desmin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2001 | 21 | 0.010 |
Why?
|
| Cystectomy | 1 | 2001 | 15 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2001 | 37 | 0.010 |
Why?
|
| Hematuria | 1 | 2001 | 18 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2002 | 112 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 97 | 0.010 |
Why?
|
| Viral Load | 1 | 2002 | 228 | 0.010 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 1981 | 5 | 0.010 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1981 | 13 | 0.010 |
Why?
|
| Sulfur Radioisotopes | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2002 | 250 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1981 | 47 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2001 | 25 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2001 | 70 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 1980 | 6 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 2001 | 59 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2001 | 59 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1980 | 29 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1980 | 29 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2000 | 31 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 1980 | 33 | 0.010 |
Why?
|
| Clonal Anergy | 1 | 2000 | 23 | 0.010 |
Why?
|
| Survivors | 1 | 2001 | 148 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1980 | 7 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 2000 | 60 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 97 | 0.010 |
Why?
|
| Adrenal Cortex | 1 | 1980 | 2 | 0.010 |
Why?
|
| Interferon Inducers | 1 | 2000 | 10 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2000 | 13 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2000 | 43 | 0.010 |
Why?
|
| Lidocaine | 1 | 1980 | 27 | 0.010 |
Why?
|
| Pichinde virus | 1 | 2000 | 19 | 0.010 |
Why?
|
| Antibodies | 1 | 2001 | 177 | 0.010 |
Why?
|
| Interphase | 1 | 2000 | 66 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2000 | 145 | 0.010 |
Why?
|
| Amino Acids | 1 | 2001 | 141 | 0.010 |
Why?
|
| Cattle | 1 | 1980 | 306 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1061 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2000 | 176 | 0.010 |
Why?
|
| Thymectomy | 1 | 1999 | 33 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2000 | 103 | 0.010 |
Why?
|
| Rabbits | 1 | 1979 | 330 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 195 | 0.010 |
Why?
|
| Carbenicillin | 1 | 1978 | 3 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1999 | 124 | 0.010 |
Why?
|
| Nephritis, Interstitial | 1 | 1978 | 13 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1999 | 132 | 0.010 |
Why?
|
| Recurrence | 1 | 2000 | 576 | 0.010 |
Why?
|
| Myocardium | 1 | 1980 | 262 | 0.010 |
Why?
|
| Immunotoxins | 1 | 1997 | 7 | 0.010 |
Why?
|
| Factor VIII | 1 | 1997 | 32 | 0.010 |
Why?
|
| Glomerulonephritis, IGA | 1 | 1997 | 7 | 0.010 |
Why?
|
| Virus Latency | 1 | 1997 | 28 | 0.010 |
Why?
|
| Interferons | 2 | 1991 | 64 | 0.010 |
Why?
|
| Haplorhini | 1 | 1977 | 14 | 0.010 |
Why?
|
| Living Donors | 1 | 1997 | 64 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1998 | 163 | 0.010 |
Why?
|
| Sheep | 1 | 1977 | 166 | 0.010 |
Why?
|
| Cytochalasin D | 3 | 1981 | 20 | 0.010 |
Why?
|
| Cross Reactions | 2 | 1987 | 123 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 253 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1979 | 451 | 0.010 |
Why?
|
| Synovial Fluid | 1 | 1976 | 29 | 0.010 |
Why?
|
| Rosette Formation | 2 | 1986 | 12 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1996 | 18 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1996 | 47 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 70 | 0.010 |
Why?
|
| Glomerulonephritis | 1 | 1976 | 30 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1976 | 126 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 1996 | 68 | 0.010 |
Why?
|
| Models, Biological | 1 | 2001 | 1140 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2000 | 646 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1997 | 367 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1996 | 290 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 1976 | 158 | 0.010 |
Why?
|
| Regeneration | 1 | 1995 | 90 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1976 | 214 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1995 | 306 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1996 | 663 | 0.010 |
Why?
|
| Cell Death | 1 | 1995 | 267 | 0.010 |
Why?
|
| Cholesterol | 1 | 1995 | 255 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 52 | 0.010 |
Why?
|
| Formamides | 1 | 1993 | 1 | 0.010 |
Why?
|
| Exonucleases | 1 | 1993 | 4 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1993 | 5 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1996 | 306 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1996 | 1582 | 0.010 |
Why?
|
| Endonucleases | 1 | 1993 | 81 | 0.010 |
Why?
|
| Causality | 1 | 1991 | 56 | 0.010 |
Why?
|
| Self Medication | 1 | 1990 | 14 | 0.010 |
Why?
|
| Rats, Inbred WF | 1 | 1990 | 56 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 23 | 0.010 |
Why?
|
| Parvoviridae | 1 | 1990 | 5 | 0.010 |
Why?
|
| Gamma Rays | 1 | 1990 | 31 | 0.010 |
Why?
|
| Clone Cells | 1 | 1990 | 106 | 0.010 |
Why?
|
| Platinum | 1 | 1990 | 20 | 0.010 |
Why?
|
| Viruses | 1 | 1991 | 79 | 0.010 |
Why?
|
| Glutathione | 1 | 1990 | 51 | 0.010 |
Why?
|
| Sulfhydryl Compounds | 1 | 1990 | 48 | 0.010 |
Why?
|
| Species Specificity | 1 | 1990 | 336 | 0.010 |
Why?
|
| Muscles | 1 | 1990 | 171 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1990 | 97 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1990 | 454 | 0.000 |
Why?
|
| Phosphonoacetic Acid | 1 | 1987 | 1 | 0.000 |
Why?
|
| Pituitary Neoplasms | 1 | 1987 | 23 | 0.000 |
Why?
|
| Cytochalasin B | 1 | 1987 | 23 | 0.000 |
Why?
|
| Vimentin | 1 | 1987 | 18 | 0.000 |
Why?
|
| Colony-Stimulating Factors | 1 | 1986 | 5 | 0.000 |
Why?
|
| Interleukin-3 | 1 | 1986 | 21 | 0.000 |
Why?
|
| Growth Substances | 1 | 1986 | 35 | 0.000 |
Why?
|
| X-Rays | 1 | 1986 | 44 | 0.000 |
Why?
|
| Lymphokines | 1 | 1986 | 66 | 0.000 |
Why?
|
| Avian Leukosis | 1 | 1985 | 1 | 0.000 |
Why?
|
| Chickens | 1 | 1985 | 91 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1986 | 278 | 0.000 |
Why?
|
| Mitogens | 1 | 1984 | 10 | 0.000 |
Why?
|
| Leukemia, Experimental | 1 | 1984 | 19 | 0.000 |
Why?
|
| Metrizamide | 1 | 1984 | 4 | 0.000 |
Why?
|
| Diatrizoate | 1 | 1984 | 4 | 0.000 |
Why?
|
| Diatrizoate Meglumine | 1 | 1984 | 5 | 0.000 |
Why?
|
| Iothalamate Meglumine | 1 | 1984 | 2 | 0.000 |
Why?
|
| Triiodobenzoic Acids | 1 | 1984 | 11 | 0.000 |
Why?
|
| Thyroiditis | 1 | 1984 | 11 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1984 | 140 | 0.000 |
Why?
|
| Mice, Mutant Strains | 1 | 1984 | 304 | 0.000 |
Why?
|
| Vaccinia | 1 | 1983 | 31 | 0.000 |
Why?
|
| Mice, Inbred C3H | 1 | 1983 | 174 | 0.000 |
Why?
|
| Pancreatitis | 1 | 1984 | 101 | 0.000 |
Why?
|
| Isoantigens | 1 | 1981 | 71 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1980 | 8 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1980 | 73 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1987 | 1539 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 252 | 0.000 |
Why?
|
| Receptors, Immunologic | 1 | 1980 | 178 | 0.000 |
Why?
|
| Microscopy, Fluorescence | 1 | 1981 | 397 | 0.000 |
Why?
|
| Microtubules | 1 | 1980 | 211 | 0.000 |
Why?
|
| Kidney Glomerulus | 1 | 1976 | 19 | 0.000 |
Why?
|
| Kidney | 1 | 1978 | 391 | 0.000 |
Why?
|
| Endocarditis, Bacterial | 1 | 1976 | 29 | 0.000 |
Why?
|